University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed

Joshi, L, Yaganti, S, Gemenetzi, M, Lightman, S, Lindfield, D, Liolios, V, Menezo, V, Shao, E and Taylor, SRJ (2013) Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed British Journal of Ophthalmology, 97 (8). pp. 1040-1044.

Full text not available from this repository.


Objective: To report the 12-month outcomes of the dexamethasone intravitreal implant in retinal vein occlusion (RVO), using an as-needed repeat injection protocol. Design: Retrospective consecutive case series of 51 eyes of 49 patients with macular oedema as a result of RVO that received an intravitreal dexamethasone implant and were followed up for at least 12 months. Results: 70% of patients responded to dexamethasone implant injection with an improvement in visual acuity (VA) and macular oedema within 3 months of injection, but only 30% of eyes gained ≥15 letters. The mean change in VA letter score at 12 months compared with baseline for branch RVO (BRVO) and central RVO (CRVO) was 5.7 ±2.3 and 11.5±11.0 EDTRS letters, respectively. 56% of patients relapsed, with the median time to relapse being 17 weeks for patients with branch RVO and 18 weeks for patients with CRVO. Repeat injections achieved similar VA gains, but the duration of effect of repeat dexamethasone implants was much shorter at 10 weeks. 14 eyes (27%) developed a significant rise in intraocular pressure, and three of these required treatment with oral acetazolamide. Four eyes with CRVO developed neovascular glaucoma during the study. Conclusions: The intravitreal dexamethasone implant does not last the 6 months implied by the retreatment protocol in the GENEVA trial, and improved results can be achieved with an as-needed retreatment protocol, particularly in CRVO. However, visual outcomes remain similar to those previously seen with triamcinolone in the SCORE study and neovascular complications remain a feature of CRVO.

Item Type: Article
Divisions : Surrey research (other units)
Authors :
Joshi, L
Yaganti, S
Gemenetzi, M
Lightman, S
Lindfield, D
Liolios, V
Menezo, V
Shao, E
Date : 1 August 2013
DOI : 10.1136/bjophthalmol-2013-303207
Depositing User : Symplectic Elements
Date Deposited : 17 May 2017 10:41
Last Modified : 24 Jan 2020 19:50

Actions (login required)

View Item View Item


Downloads per month over past year

Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800